Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α1 -adrenergic receptor antibodies.

Cerebrovascular abnormality is frequently accompanied by cognitive dysfunctions, such as dementia. Antibodies against the alpha(1)-adrenoceptor (alpha(1)-AR) can be found in patients with Alzheimer's disease with cerebrovascular disease, and have been shown to affect the larger vessels of the brain in rodents. However, the impact of alpha(1)-AR antibodies on the cerebral vasculature remains unclear. In the present study, we established a neuroimaging method to measure the relative cerebral blood volume (rCBV) in small rodents with the ultimate goal to detect changes in blood vessel density and/or vessel size induced by alpha(1)-AR antibodies. For this purpose, mapping of Delta R-2* and Delta R-2 was performed using MRI at 9.4 T, before and after the injection of intravascular iron oxide particles (ferumoxytol). The change in the transverse relaxation rates (Delta R-2*, Delta R-2) showed a significant rCBV decrease in the cerebrum, cortex and hippocampus of rats (except hippocampal Delta R-2), which was more pronounced for Delta R-2* than for Delta R-2. Immunohistological analyses confirmed that the alpha(1)-AR antibody induced blood vessel deficiencies. Our findings support the hypothesis that alpha(1)-AR antibodies lead to cerebral vessel damage throughout the brain, which can be monitored by MRI-derived rCBV, a non-invasive neuroimaging method. This demonstrates the value of rCBV estimation by ferumoxytol-enhanced MRI at 9.4 T, and further underlines the significance of this antibody in brain diseases involving vasculature impairments, such as dementia. Copyright (C) 2014 John Wiley & Sons, Ltd.